Beyond a Universal Cut-Off: [18F]FET-PET Metrics for Distinguishing High-Grade Glioma Recurrence from Treatment-Related Changes
Authors:
- Pier Paolo BertiPBPier Paolo Berti
- Alessandro SpimpoloASAlessandro Spimpolo
- Leda LorenzonLLLeda Lorenzon
- Davide DrusianiDDDavide Drusiani
- Matteo PresaMPMatteo Presa
- Luca ZavattoLuca Zavatto
- Paolo Cipriano CecchiPCPaolo Cipriano Cecchi
- Davide CostazzaDCDavide Costazza
- Vania PirilloVPVania Pirillo
- Matteo BonattiMatteo Bonatti
- Francesco ErdiniFEFrancesco Erdini
- Nadia OberhoferNONadia Oberhofer
Open Access
- 9 October 2026
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 16 (10) , 1085
Abstract
Background/Objectives: Differentiating tumour recurrence from treatment-related changes (TRC) after multimodal treatment of high-grade gliomas (HGGs) remains challenging because of the overlap in imaging findings on conventional magnetic resonance. This study compared the diagnostic performance of the main static semiquantitative O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography ([18F]FET-PET) parameters and assessed the diagnostic contribution of qualitative tracer uptake. Methods: This retrospective single-centre study included 77 scans from 61 adult patients with previously resected and chemoradiotherapy-treated HGGs undergoing [18F]FET-PET for suspected recurrence. Standardised uptake values (SUVs), tumour-to-background ratios (TBRs), and metabolic tumour volume (MTV) were analysed. Recurrence was determined using a composite histopathological and clinical–radiological reference standard. Diagnostic performance was assessed using receiver operating characteristic analysis, Youden-derived cut-offs and DeLong comparisons. Internal validation was performed by using patient-grouped five-fold cross-validation, in which cut-offs were re-derived within each training partition and applied to the held-out partition. Results: Forty-nine scans were classified as recurrence and 28 as TRC. All semiquantitative parameters except MTV were significantly higher in recurrent disease after false-discovery-rate correction. TBR mean ratio showed the highest accuracy (AUC, 0.80; cut-off, 1.85; sensitivity, 77.6%; specificity, 75.0%), followed by SUV max (AUC, 0.793). Neither prespecified comparison among TBR parameters was significant. The presence of pathological uptake achieved 100% sensitivity, 42.9% specificity, 100% NPV, and 79.2% accuracy. MTV was non-discriminative (AUC, 0.499). SUV max differed significantly between scanners (p = 0.008). Conclusions: Static semiquantitative [18F]FET-PET parameters, except MTV, showed comparable moderate-to-good performance for distinguishing recurrence from TRC. TBRmean may represent a pragmatic primary marker due to its background normalisation reduction of scanner-related variability. Guideline-recommended thresholds should be regarded as reference values requiring local validation and, when appropriate, centre- and protocol-specific calibration.Keywords
This publication has 35 references indexed in Scilit:
- FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled studyNeuroradiology, 2024
- 18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysisJournal of Neuro-Oncology, 2022
- Static FET PET radiomics for the differentiation of treatment-related changes from glioma progressionJournal of Neuro-Oncology, 2022
- Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRIEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Radiomics in Oncological PET/CT: a Methodological OverviewNuclear Medicine and Molecular Imaging, 2019
- Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniquesJournal of Magnetic Resonance Imaging, 2018
- Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2018
- Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomideCancer, 2008
- Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent gliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004